Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.
about
The Evolution of Therapies in Non-Small Cell Lung CancerVinorelbine-related cardiac events: a meta-analysis of randomized clinical trials.The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials.Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.Gemcitabine and Vinorelbine (GemVin) RegimenGemcitabine for the treatment of advanced nonsmall cell lung cancerCardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.Treating advanced non-small cell lung cancer in the elderly.The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).Five years managing metastatic non-small cell lung cancer: experience at a teaching hospital.Role of gemcitabine in cancer therapy.Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.Introducing a new entity: chemotherapy-induced arrhythmia.Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients.Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms
P2860
Q26786932-42C6566A-9DC4-481E-A1F8-AC8381DAECDDQ31038884-D3F23125-DC42-4096-8FD7-F2AC1D9FC273Q33343275-53561A5E-DE9B-49A9-8BAB-4E36764F968CQ33411167-AD90C1CC-794E-44D1-9E87-2BC4350FC65FQ33426486-619F4400-D7B5-4305-879B-5E4507F4D211Q33774738-30583DCD-14F3-4B8B-BB56-D210D2386FCCQ33915997-F4AB2845-2ABA-461E-B4A6-554105F56DC3Q34571555-F1CCF869-BDE8-4748-9298-CDD493473B5EQ35076283-57199B34-D955-4B93-B041-A6C5CCB36EA0Q35642373-5FA15D53-9B35-4C87-8E9B-35CFFC7C28F5Q35866141-B35B5EFE-7A85-4CFD-AB27-39DAEED353FFQ36429373-CCBBC025-F674-4FC1-A4CD-B5125230896DQ37157395-89615A14-CC2A-457C-9A0E-FFD9DCE06145Q37607920-5CD25552-CB29-4DCB-81CA-0263D016F619Q38149819-22A5B8FA-7DCC-47AF-B5A1-F17A94677263Q39095223-7A41DA27-9B64-428D-B8E5-13912C230D4AQ44128419-8335E7A4-4F96-4D5E-8A56-83F346DC93B9Q45114042-8592E508-EE22-4EA9-A08F-47629FEA28F1Q46804039-1562BB0D-D37C-41A7-A9FA-91F98CAC9F5BQ48706070-B9287977-E9D9-4636-B7D9-E429490D3648Q58554222-6993E905-73FD-4EC4-B5D1-C342CB1F32DB
P2860
Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Activity and toxicity of gemci ...... tudy (MILES) randomized trial.
@ast
Activity and toxicity of gemci ...... tudy (MILES) randomized trial.
@en
type
label
Activity and toxicity of gemci ...... tudy (MILES) randomized trial.
@ast
Activity and toxicity of gemci ...... tudy (MILES) randomized trial.
@en
prefLabel
Activity and toxicity of gemci ...... tudy (MILES) randomized trial.
@ast
Activity and toxicity of gemci ...... tudy (MILES) randomized trial.
@en
P2093
P1433
P1476
Activity and toxicity of gemci ...... tudy (MILES) randomized trial.
@en
P2093
C Gridelli
G Gasparini
G P Ianniello
L Frontini
L Manzione
MILES Investigators
S Cigolari
P304
P356
10.1016/S0169-5002(00)00194-X
P577
2001-02-01T00:00:00Z